Celgene’s most recent trend suggests a bearish bias. One trading opportunity on Celgene is a Bear Call Spread using a strike $160.00 short call and a strike $170.00 long call offers a potential 5.15% return on risk over the next 12 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $160.00 by expiration. The full premium credit of $0.49 would be kept by the premium seller. The risk of $9.51 would be incurred if the stock rose above the $170.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Celgene is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Celgene is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
3 Future Stars in Big Pharma’s Best Pipeline
Sun, 03 Nov 2013 13:35:57 GMT
Motley Fool – Johnson & Johnson is no stranger to developing strong pharmaceuticals for the long term, but which drugs should you keep an eye on that will keep this company’s business on track in the future?
CELGENE CORP /DE/ Financials
Sat, 02 Nov 2013 17:04:35 GMT
Some Leading Names Stumble, But Indexes Hold Firm
Fri, 01 Nov 2013 22:31:00 GMT
Investor’s Business Daily – Some Leading Names Stumble, But Indexes Hold Firm
Biotech Stock Mailbag: Chelsea’s FDA Panel, Ariad’s Future, Bio-Bubble Update
Fri, 01 Nov 2013 10:00:00 GMT
TheStreet – I ate three pounds of Halloween candy this week but was still able to write the Biotech Stock Mailbag. @adamfeuerstein hows bout a quick take on $CHTP advisory panel. Let me start by recapping my recent history with Chelsea Therapeutics and Northera, the experimental treatment for neurogenic orthostatic hypotension (NOH) — a chronic disease characterized by dangerously low blood pressure.
CommScope, Enzymotec Above IPO Prices As Earnings Loom
Thu, 31 Oct 2013 21:31:00 GMT
Investor’s Business Daily – CommScope, Enzymotec Above IPO Prices As Earnings Loom
Also on Market Tamer…
Follow Us on Facebook